Use of a multi-gene pharmacogenetic panel reduces adverse drug effects

Swen et al.(1) examine the utility of multi-gene pharmacogenetic testing in a large multi-national cohort. They show fewer adverse drug reactions among patients receiving testing and prescribing recommendations based on genotype results compared with those receiving usual care.

Detalles Bibliográficos
Autores principales: Cavallari, Larisa H., Johnson, Julie A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213803/
https://www.ncbi.nlm.nih.gov/pubmed/37084734
http://dx.doi.org/10.1016/j.xcrm.2023.101021

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10213803/
https://www.ncbi.nlm.nih.gov/pubmed/37084734
http://dx.doi.org/10.1016/j.xcrm.2023.101021

Ejemplares similares